Back to search

Article

Discontinuation Risk from Adverse Events: Immunotherapy Alone vs. Combined with Chemotherapy: A Systematic Review and Network Meta-analysis

2023-10-24

Abstract excerpt

<h4>Background: </h4> While immunotherapy combined with chemotherapy (Chemo-IO) is generally recognized for providing superior outcomes compared to monotherapy (mono-IO), it is associated with a higher incidence of treatment-related adverse events (TRAEs). However, there have been few direct comparisons of treatment discontinuation rates between these two treatments. In this study, we compared the rates of treatme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
632b3291-039d-5f7a-9a0a-02bed4a68184
DOI
10.21203/rs.3.rs-3433325/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discontinuation Risk from Adverse Events: Immunotherapy Alone vs. Combined with Chemotherapy: A Systematic Review and Network Meta-analysisDOI 10.21203/rs.3.rs-3433325/v1
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity
Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity
Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.Semantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
[Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].Semantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity
Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.Semantic proximity
Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.Semantic proximity
Select a neighboring publication to make it the new centre.